CommercialCoverageMedium impact
06.02.17h, Serodiagnosis of Inflammatory Bowel Disease (IBD) and the Prometheus® IBD sgi Diagnostic™ Test
Independence Blue Cross·Gastroenterology, Internal Medicine, Family Medicine·Pharmacy
Effective date
Jun 10, 2026
We identified it
Jun 19, 2026
Summary
Policy 06.02.17h regarding serodiagnosis of inflammatory bowel disease (IBD) and the Prometheus® IBD sgi Diagnostic™ Test has been reissued under the Pharmacy category. This policy update affects commercial plans and becomes effective June 10, 2026.
Action Required
Before June 10, 2026: Billing team should review the full policy text at the provided URL to understand specific coverage criteria and billing requirements for IBD serodiagnostic testing and the Prometheus® IBD sgi Diagnostic™ Test. Update billing protocols and prior authorization workflows as needed based on the complete policy details.